DOW JONES21,413.44+469.93 2.24%
S&P 5002,526.90+56.40 2.28%
NASDAQ7,487.31+126.73 1.72%

Chardan Capital Initiates Coverage On NeuBase Therapeutics with Buy Rating, Announces $14 Price Target

Chardan Capital analyst Keay Nakae initiates coverage on NeuBase Therapeutics (NASDAQ:NBSE) with a Buy rating and a $14 price target.

Benzinga · 03/06/2020 14:26

Chardan Capital analyst Keay Nakae initiates coverage on NeuBase Therapeutics (NASDAQ:NBSE) with a Buy rating and a $14 price target.